Andrea Dassie

Dr. Andrea Dassie

Centro di Riferimento Oncologico, Aviano, Italy
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
GPGiovanni Pirrone
Giovanni Pirrone
FMFABIO MATRONE
FABIO MATRONE
PCPaola Chiovati
Paola Chiovati
SMStefania Manente
Stefania Manente
ADAnnalisa Drigo
Annalisa Drigo
MAMichele Avanzo
Michele Avanzo
The aim of this study is to predict local failure after partial prostate re-irradiation for the treatment of isolated locally recurrent prostate cancer by using a machine learning classifier based on radiomic features from pre-treatment computed tomography (CT), positron-emission tomography (PET) and biological effective dose distribution (BED) of the radiotherapy plan. The analysis was conducted on a monocentric dataset of 43 patients with evidence of isolated intraprostatic recurrence of prostate cancer after primary external beam radiotherapy. All patients received partial prostate re-irradiation delivered by volumetric modulated arc therapy. The gross tumor volume (GTV) of each patient was manually contoured from planning CT, choline-PET and dose maps. An ensemble machine learning pipeline including unbalanced data correction and feature selection was trained using the radiomic and dosiomic features as input for predicting occurrence of local failure. The model performance was assessed using sensitivity, specificity, accuracy and area under receiver operating characteristic curves of the score function in 10-fold cross validation repeated 100 times. Local failure was observed in 13 patients (30%), with a median time to recurrence of 36.7 months (range = 6.1–102.4 months). A four variables ensemble machine learning model resulted in accuracy of 0.62 and AUC 0.65. According to our results, a dosiomic machine learning classifier can predict local failure after partial prostate re-irradiation.

25 October 2011 in Cancers
Verified
Journal Article
Open access
PDF file
MMMaurizio Mascarin
Maurizio Mascarin
FGFrancesca Maria Giugliano
Francesca Maria Giugliano
ECElisa Coassin
Elisa Coassin
ADAnnalisa Drigo
Annalisa Drigo
PCPaola Chiovati
Paola Chiovati
MTMauro Gaetano Trovò
Mauro Gaetano Trovò
Helical Tomotherapy (HT) is a highly conformal image-guided radiation technique, introduced into clinical routine in 2006 at the Centro di Riferimento Oncologico Aviano (Italy). With this new technology, intensity-modulated radiotherapy (IMRT) is delivered using a helicoidal method. Here we present our dosimetric experiences using HT in 100 children, adolescents and young adults treated from May 2006 to February 2011. The median age of the patients was 13 years (range 1–24). The most common treated site was the central nervous system (50; of these, 24 were craniospinal irradiations), followed by thorax (22), head and neck (10), abdomen and pelvis (11), and limbs (7). The use of HT was calculated in accordance to the target dose conformation, the target size and shape, the dose to critical organs adjacent to the target, simultaneous treatment of multiple targets, and re-irradiation. HT has demonstrated to improve target volume dose homogeneity and the sparing of critical structures, when compared to 3D Linac-based radiotherapy (RT). In standard cases this technique represented a comparable alternative to IMRT delivered with conventional linear accelerator. In certain cases (e.g., craniospinal and pleural treatments) only HT generated adequate treatment plans with good target volume coverage. However, the gain in target conformality should be balanced with the spread of low-doses to distant areas. This remains an open issue for the potential risk of secondary malignancies (SMNs) and longer follow-up is mandatory.

1 September 1992 in The European Physical Journal A
Verified
Journal Article
Closed access
PDF file
GAG. Des Angelis
G. Des Angelis
DBD. Bazzacco
D. Bazzacco
SBS. Beghini
S. Beghini
ABA. M. Bizzeti-Sona
A. M. Bizzeti-Sona
PBP. G. Bizzeti
P. G. Bizzeti
FTFilippo Terrasi
Filippo Terrasi

14 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ACAurora Corso
Aurora Corso
NMNiki Martinel
Niki Martinel
MRMubashara Rehman
Mubashara Rehman
JSJoseph Stancanello
Joseph Stancanello
Micheloni christianMicheloni christian
Micheloni christian
MAMichele Avanzo
Michele Avanzo
Background/Objectives: Dental metallic implants cause severe streaking artifacts in kilovoltage CT (kVCT), compromising dose calculation in radiotherapy (RT) treatment planning. The purpose of this study is to assess the dosimetric agreement of synthetic MVCT (sMVCT) images generated from artifact-affected kVCT using a deep learning network with respect to true MVCT (tMVCT) acquired at the treatment machine. Methods: Nineteen head and neck cancer patients with dental metallic implants treated with RT were included. Planning kVCT images were converted to sMVCT using Metal Artifact Reduction through Domain Transformation Network (MAR-DTN), a UNet-inspired deep learning network. The sMVCT images were rigidly registered to true MVCT (tMVCT) acquired on the Hi-Art II Tomotherapy system. Mean Hounsfield Unit (HU) values were compared across seven structures (thyroid, bilateral parotids, brainstem, spinal cord, GTV, PTV70) using pairwise Wilcoxon tests and Two One-Sided Tests (TOST) for statistical equivalence within a pre-specified margin of ±20 HU (corresponding to a 2% deviation in physical density). Dose distributions were recalculated on sMVCT using the AAA algorithm and compared to reference tMVCT-based plans via dose–volume histogram (DVH) metrics, evaluated for equivalence by TOST within a margin of ±2% of the prescribed dose (±142 cGy of 70.95 Gy), and via 3D gamma index, evaluated by one-sided non-inferiority test against the clinically accepted thresholds of 90% (2 mm/2%) and 95% (3 mm/3%). A pre-specified sensitivity analysis was performed by repeating all comparisons on the strictly independent sub-cohort (n = 16) excluding three patients drawn from the MAR-DTN training set. Results: All seven anatomical structures showed statistical equivalence between sMVCT and tMVCT under the ±20 HU margin (TOST p < 0.05; mean HU differences in the range −1.1 to +8.4 HU; all Wilcoxon p > 0.05). All nine DVH metrics achieved formal dosimetric equivalence within ±2% of the prescribed dose (TOST p < 0.05). Mean 3D gamma pass rates were 94.3% (95% CI: 89.3–97.1) for the 2 mm/2% criterion and 97.6% (95% CI: 94.8–99.0) for the 3 mm/3% criterion, both formally non-inferior to the respective clinical thresholds (p < 0.0001). Residual gamma failures were concentrated at the patient surface, consistent with inter-session repositioning uncertainty rather than errors in synthetic image generation. Sensitivity analysis on the n = 16 sub-cohort confirmed all conclusions, with mean HU and DVH differences smaller than in the full cohort for the structures showing the largest mean differences, and comparable for the remaining structures, with all TOST equivalence and gamma non-inferiority tests confirmed in both cohorts. Conclusions: sMVCT images generated via MAR-DTN show dosimetric agreement with physically acquired tMVCT in head and neck patients with dental implants, formally demonstrated by TOST equivalence within ±2% of prescribed dose for all DVH metrics. The combined HU and gamma index framework presented here represents a promising quality assurance approach for AI-based synthetic imaging tools in radiotherapy, pending validation in larger prospective multicentre cohorts.

11 November 2026 in Physica Medica
Verified
Journal Article
Closed access
LTLicia Toscano
Licia Toscano
MAMichele Avanzo
Michele Avanzo
SFStefano Fracon
Stefano Fracon
SMSamuele Massarut
Samuele Massarut
LBLoredana Barresi
Loredana Barresi
ADAndrea Dassie
Andrea Dassie